Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
該当コードがありません。
から:
次の項目別のソート:
日付受信時刻ニュースソース見出しコード企業名
2024/06/0400 : 41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KHCKraft Heinz Company
2024/06/0400 : 40Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]USOTC:RYLBFRoyal Bank (PK)
2024/06/0400 : 40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SNNUFSmith and Nephew Plc (PK)
2024/06/0400 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JLLJones Lang LaSalle Inc
2024/06/0400 : 40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:DNNDenison Mines Corp
2024/06/0400 : 40Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]USOTC:MSTLWMorgan Stanley (PK)
2024/06/0400 : 40GlobeNewswire Inc.Signaux Girod : Publication relative aux actions et droits de vote au 31.05.2024LSE:0NASSignaux Girod Sa
2024/06/0400 : 40GlobeNewswire Inc.Announcement of the total number of voting rights as at 31 May 2024EU:KBCAKBC Ancora SA
2024/06/0400 : 40GlobeNewswire Inc.Signaux Girod : Publication relative aux actions et droits de vote au 31.05.2024EU:ALGIRSignaux Girod
2024/06/0400 : 40PR Newswire (US)Sun Life U.S. lands in the top 10 of Milwaukee Journal Sentinel Top Places to WorkTSX:SLFSun Life Financial Inc
2024/06/0400 : 40PR Newswire (US)Sun Life U.S. lands in the top 10 of Milwaukee Journal Sentinel Top Places to WorkNYSE:SLFSun Life Financial Inc
2024/06/0400 : 40GlobeNewswire Inc.Annonce du nombre total des droits de vote au 31 mai 2024EU:KBCAKBC Ancora SA
2024/06/0400 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GSRMUGSR II Meteora Acquisition Corporation
2024/06/0400 : 38Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]USOTC:RYLBFRoyal Bank (PK)
2024/06/0400 : 38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:TRUTransUnion
2024/06/0400 : 38Business WireProofpoint Announces Expansion of Flagship Annual ‘Protect’ Conference to Showcase Latest Innovations in Human-Centric Cybersecurity to Growing Customer Base
2024/06/0400 : 37Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]USOTC:MSTLWMorgan Stanley (PK)
2024/06/0400 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JLLJones Lang LaSalle Inc
2024/06/0400 : 37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:OMIOwens and Minor Inc
2024/06/0400 : 37PR Newswire (US)BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx
2024/06/0400 : 37PR Newswire (US)Sentry partners with Falvey Insurance Group to expand into marine cargo
2024/06/0400 : 37PR Newswire (US)BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx
2024/06/0400 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERIEErie Indemnity Company
2024/06/0400 : 35Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]USOTC:MSTLWMorgan Stanley (PK)
2024/06/0400 : 35GlobeNewswire Inc.Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious DiseasesEU:VLAValneva SE
2024/06/0400 : 35GlobeNewswire Inc.Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious DiseasesTG:AYJValneva SE
2024/06/0400 : 35GlobeNewswire Inc.Programme de rachat d'actions propres - Déclaration des transactions sur actions propres réalisées du 27 mai 2024 au 31 mai 2024LSE:0OA7Assystem Sa
2024/06/0400 : 35GlobeNewswire Inc.Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious DiseasesEU:VLAValneva SE
2024/06/0400 : 35GlobeNewswire Inc.Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious DiseasesVLAP
2024/06/0400 : 35GlobeNewswire Inc.Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious DiseasesLSE:0OB3Valneva Se